{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:49Z","timestamp":1782337249360,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Abbvie Pharmaceuticals"},{"name":"Adaptive Biotechnologies"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmacyclics"},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.hoc.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T10:21:20Z","timestamp":1557310880000},"page":"613-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Benjamin","family":"Diamond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2019.03.002_bib1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.002_bib2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New Approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.002_bib3","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","article-title":"Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2019.03.002_bib4","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.002_bib5","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","article-title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma","volume":"121","author":"Vegilante","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib6","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2019.03.002_bib8","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib9","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.002_bib10","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V128.22.145.145","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 LyMa trial of the LYSA\/Goelams group","volume":"128","author":"Le Gouill","year":"2016","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.hoc.2019.03.002_bib12","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.002_bib13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib14","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A\u00a0phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma: SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib15","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib16","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of MCL after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a randomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"10044","key":"10.1016\/j.hoc.2019.03.002_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem cell transplantation in patients aged 65 years or younger with MCL (MCL Younger): a randomized, open-label, phase 3 trial of the European Mantle Cell Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.002_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A\u00a0phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2019.03.002_bib20","doi-asserted-by":"crossref","unstructured":"Merryman RW, Kahl BS. Rituximab\/bendamustine and rituximab\/cytarabine (RB\/RC) induction chemotherapy for transplant-eligible patients with mantle cell lymphoma: a pooled Analyis of two phase 2 clinical trials and off-trial Experience. Poster Presented at 2018 ASH. San Diego, CA, December, 2018.","DOI":"10.1182\/blood-2018-99-110520"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.002_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2019.03.002_bib22","first-page":"100","article-title":"Prognostic value of proliferation, cytology, and growth pattern in mantle cell lymphoma: results from randomized trials of the European MCL network","volume":"33","author":"Hoster","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib23","unstructured":"Delfau-Larue M, Klapper W, Berger F, et\u00a0al. CDKN2A and TP53 deletions predict adverse outcome in younger mantle cell lymphoma patients, independent of treatment and MIPI. Presented at the ASH Annual Meeting and Exposition. Orlando, FL, December 5\u20138, 2015."},{"key":"10.1016\/j.hoc.2019.03.002_bib24","unstructured":"Delfau-Larue M-H, Hoster E, et\u00a0al. CDKN2A and TP53 deletions predict adverse outcomes in younger mantle cell lymphoma patients, independent of treatment and MIPI. Presented at the ASH Annual meeting and Exposition. Orlando, FL, December 5\u20138, 2015."},{"issue":"15","key":"10.1016\/j.hoc.2019.03.002_bib25","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.V128.22.147.147","article-title":"Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2019.03.002_bib27","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-ritximab or R-CHOP\/R-CVP in first line treatment of indolent NHL or MCL: the Bright study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.hoc.2019.03.002_bib28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicenter, randomized, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.002_bib29","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.03.002_bib31","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2019.03.002_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V124.21.148.148","article-title":"Frontline therapy with RiBVD regimen elicits high clinical and molecular response rates and long PFS in elderly patients with mantle cell lymphoma; final results of a prospective phase II trial by the LYSA group","volume":"124","author":"Gressin","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2019.03.002_bib33","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.002_bib34","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assisted by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib35","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood.V128.22.146.146","article-title":"Molecular monitoring and tailored strategy with pre-emptive rituximab treatment for molecular relapse: results from the Nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"128","author":"Kolstad","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.V126.23.337.337","article-title":"Bortezomib maintenance versus consolidation following aggressive immunochemotherapy and autologous stem cell transplant for untreated mantle cell lymphoma: CALGB 50403","volume":"126","author":"Kaplan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib38","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine, and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma","volume":"48","author":"Rodriguez","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2019.03.002_bib39","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/10428190801993470","article-title":"Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"49","author":"Witzig","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2019.03.002_bib40","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-KB activation in mantle cell lymphoma B-cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.002_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes, and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.hoc.2019.03.002_bib43","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.002_bib44","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2015.60","article-title":"Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma","volume":"29","author":"Hess","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2019.03.002_bib45","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A\u00a0phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.002_bib46","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limited the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib47","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood.V126.23.3935.3935","article-title":"Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma","volume":"126","author":"Cunningham","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2019.03.002_bib48","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.18632\/oncotarget.2253","article-title":"Dual PI3K\/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma","volume":"5","author":"Rosich","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2019.03.002_bib49","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Younes A, et\u00a0al. Phase I\/II clinical trial of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. Presented at ASCO. Chicago, IL, June 4, 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.7520"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.002_bib50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.13456","article-title":"Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE)","volume":"170","author":"Goy","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.002_bib51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.hoc.2019.03.002_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.002_bib54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10020","key":"10.1016\/j.hoc.2019.03.002_bib55","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma: an international, randomized, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2019.03.002_bib56","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.hoc.2019.03.002_bib57","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2019.03.002_bib58","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.03.002_bib59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T\u00a0cells directed against CD19 (CTL019) in patients with relapsed or refractory lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.002_bib60","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2019.03.002_bib61","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:11:56Z","timestamp":1760184716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858819300358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0889858819300358"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.03.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}